Monoclonal Antibody Drug Conjugates for Cancer Therapy

Abstract

Antibody drug conjugates (ADCs) con- stitute a family of cancer therapeutics designed to preferentially direct a cytotoxic drug to cells express- ing a cell-surface antigen recognized by an antibody. The antibody and drug are linked through chemistries that enable release ofthe cytotoxic drug or drugadduct upon internalization and digestion of the ADC by the cell. Over 40 distinct ADCs, targeting an array of antigens and utilizing a variety of drugs and linkers, are undergoing clinical evaluation. This review primarily covers ADCs that have advanced to clinical investigation with a particular emphasis on how the individual targets, linker chemistries, and appended drugs influence their behavior. Address